|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
|
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
May 2023 |
Frontiers in Oncology |
Aplastic Anemia |
|
How we diagnose Myelodysplastic syndromes |
Sep 2024 |
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
|
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
Mar 2019 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Treatment of lower-risk myelodysplastic syndromes |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
Apr 2023 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
